Jabbour Reports Top Takeaways From ASH 2023 of Olverembatinib in CML and ALL

Dr Jabbour discusses the activity and the utilization of olverembatinib in chronic myeloid leukemia and expanded upon the role that TKIs can play in the management of malignancies beyond chronic myeloid leukemia and acute lymphoblastic leukemia.

Related Keywords

Houston ,Texas ,United States ,Elias Jabbour ,Ascentage Pharma ,Ryan Scott ,Twitter ,Linkedin ,Department Of Leukemia ,Facebook ,Division Of Cancer Medicine ,University Of Texas Md Anderson Cancer Center ,Live On Air ,Cancer Medicine ,Cancer Center ,Onclive On Air ,Apple Podcasts ,Google Podcasts ,Amazon Music ,D ,The University Of Texas Md Anderson Cancer Center ,